Covered recipient · General Payments record
ELIZABETH S KLINGS
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2019–2024
$44,136.82
- Reported across 62 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,480.00 | 4 |
| Travel and Lodging | $1,255.68 | 3 |
| Food and Beverage | $536.89 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $5,355.00 | 2 |
| PFIZER INC. | $4,238.47 | 3 |
| CSL Behring | $1,525.68 | 6 |
| Actelion Pharmaceuticals US, Inc. | $153.42 | 5 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $5.96 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078891183 | CMS |
| Actelion Pharmaceuticals US, Inc. | $17.21 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078891189 | CMS |
| Actelion Pharmaceuticals US, Inc. | $11.10 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078891265 | CMS |
| Actelion Pharmaceuticals US, Inc. | $23.82 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078891345 | CMS |
| Actelion Pharmaceuticals US, Inc. | $95.33 | 05/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078891317 | CMS |
| CSL Behring | $125.00 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134628083 | CMS |
| CSL Behring | $741.57 | 12/05/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134628085 | CMS |
| CSL Behring | $218.85 | 12/05/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134628087 | CMS |
| CSL Behring | $60.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134628089 | CMS |
| CSL Behring | $85.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134628091 | CMS |
| CSL Behring | $295.26 | 12/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134628093 | CMS |
| Novo Nordisk AS | $4,462.50 | 10/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096553123 | CMS |
| Novo Nordisk AS | $892.50 | 11/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096553213 | CMS |
| PFIZER INC. | $450.00 | 03/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131798054 | CMS |
| PFIZER INC. | $113.47 | 10/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131599791 | CMS |
| PFIZER INC. | $3,675.00 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1130891792 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.